ReviewFrontiers in physiology2021
Ectodysplasin A/Ectodysplasin A Receptor System and Their Roles in Multiple Diseases.
Review in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Long-Term PMAnnals of the American Thoracic Society · 2025Pooled it
- Plasma proteomic signatures predict incident benign prostatic hyperplasia: a prospective cohort study of 20 996 men.Journal of global health · 2026Article
- Ectodysplasin-A (EDA) Signaling Cross-Talk in Skeletogenesis.Calcified tissue international · 2026Review
- Systematic analyses uncover plasma proteins linked to incident cardiovascular diseases.Protein & cell · 2026Article
- Article
- Vitamin B12 Protects Against Early Diabetic Kidney Injury and Alters Clock Gene Expression in Mice.Biomolecules · 2025Article
- The Roles of EDA2R in Ageing and Disease.Aging cell · 2025Review
- Proteomic analysis identifies novel molecular signatures and immune-metabolic pathways in rheumatoid arthritis-associated interstitial lung disease.Biomedical reports · 2025Article
- Associations of 2923 Olink proteins with demographic, lifestyle, environmental and health characteristics in middle-aged Chinese adults.European journal of epidemiology · 2025Article
- Global and tissue-specific transcriptomic dysregulation in human aging: Pathways and predictive biomarkers.GeroScience · 2025Article
- High serum EDA concentration is associated with metabolic syndrome and its determinants.Acta diabetologica · 2025Article
- Differential memory enrichment of cytotoxic CD4 T cells in Parkinson's disease patients reactive to α-synuclein.NPJ Parkinson's disease · 2025Article
- Hematopoietic effects of Fufang E'jiao Jiang revealed by microbiome, metabolome and transcriptome analyses: a multi-omics strategy.Frontiers in immunology · 2025Article
- Multi-omics and AI-driven advances in miRNA-mediated hair follicle regulation in cashmere goats.Frontiers in veterinary science · 2025Review
- Transcriptome analysis identifies EDA1 variants disrupt FOSB-mediated regulation of odontogenic epithelial cell behaviors during dental germ development.Frontiers in cell and developmental biology · 2025Article
- Ectodysplasin-A2 receptor (EDA2R) knockdown alleviates myocardial ischemia/reperfusion injury through inhibiting the activation of the NF-κB signaling pathway.Experimental animals · 2024Article
- Identification of costimulatory molecule signatures for evaluating prognostic risk in non-small cell lung cancer.Heliyon · 2024Article
- EDA2R reflects the acute brain response to cranial irradiation in liquid biopsies.Neuro-oncology · 2024Article
- Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis.The Journal of molecular diagnostics : JMD · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ectodysplasin A (EDA) is a member of the tumor necrosis factor (TNF) family of ligands that was initially reported to induce the formation of various ectodermal derivatives during normal prenatal development. EDA exerts its biological activity as two splice variants, namely, EDA-A1 and EDA-A2. The former binds to the EDA receptor (EDAR), resulting in the recruitment of the intracellular EDAR-associated death domain (EDARADD) adapter protein and the activation of the NF-κB signaling pathway, while the latter binds to a different receptor, EDA2R, also known as X-linked ectodermal dysplasia receptor (XEDAR). Inactivation mutation of the EDA gene or the genes coding for its receptors can result in hypohidrosis ectodermal dysplasia (HED), a condition that is characterized by oligotrichosis, edentulosis or oligodontia, and oligohidrosis or anhidrosis. Recently, as a new liver factor, EDA is gradually known and endowed with some new functions. EDA levels were observed to be upregulated in several metabolic diseases, such as non-alcoholic fatty liver disease (NAFLD), obesity, and insulin resistance. In addition, EDA and its receptors have been implicated in tumor pathogenesis through the regulation of tumor cell proliferation, apoptosis, differentiation, and migration. Here, we first review the role of EDA and its two-receptor system in various signaling pathways and then discuss the physiological and pathological roles of EDA and its receptors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.